Recently, our report revealed the clinical insulin sensitizer metformin modulates PDIA4 and adiponectin expression and improves obesity-associated conditions in both in vitro adipocytes and in vivo mouse models (67). The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.